GIP/GLP-1 & amylin agonists × hypoglycaemia

SynthesisFrontiers in endocrinology2023

A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?

Zhuqing Meng et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 9,818 people · 2023

Not counted

Raised hypoglycaemia

3.8×1.2× to 12×

Bigger than 9 in 10 on the map

As reported

RR 3.83, 95% CI 1.19–12.3

One number in the abstract

the abstract, start to end

(tirzepatide 15mg, pooled RR=3.83, 95% CI [1.19- 12.30],

← favours treatmentfavours comparator →
could be chance
Hypoglycaemia
RR 3.831.19–12.3
GLP-1 receptor agonistsGIP/GLP-1 & amylin agonistsHypoglycaemia
1 / 3

15 papers cite it

2023
2024
2025
2026
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 37051199